Dongbang FTL has committed to producing high-quality pharmaceuticals in the fields of synthetic API(Active Pharmaceutical Ingredients), natural API, and finished pharmaceuticals products, all based on the core value of 'quality' and backed by exceptional technical expertise.
In the area of synthetic API, we have received GMP certifications from the Korea FDA, Japan's PMDA, Australia's TGA, and France's ANSM. Currently, we are supplying a wide range of API, such as anti-inflammatory analgesics, antihypertensive drugs, cardiovascular disease treatments, diabetes medications, and urinary system treatments, to global pharmaceuticals.
We have firmly established our position in the Japanese market with over 20 J-DMF(Japanese Drug Master Files) products, and we are expanding our business in Europe with more than 10 EU-DMF(European Union Drug Master Files) products.
Moreover, we are currently conducting 35 CMC(Chemistry, Manufacturing and Controls) and CDMO (Contract Development and Manufacturing Organization) projects in collaboration with leading domestic and international global pharmaceutical and biotech companies and research institutions.
In addition, based on our technology specialized in molecule structure design and molecule synthesis, we are expanding investment in our own new drug development and making tangible results using PROTAC technology.
In the area of natural product-based pharmaceuticals, we have been the first in Korea to achieve GMP certification for herbal API. We are continuously investing in the development of new herbal substances and new drug research, holding multiple patents. In collaboration with external organizations, we are developing an injectable material for hair loss treatment using human hair keratin and are preparing for clinical trials. We are also conducting Phase 2 clinical trials for the treatment of benign prostatic hyperplasia with HBX-6, which utilizes the modified Gagamnaegohwan (加減內固丸), derived from the Donguibogam (東醫寶鑑, The Encyclopedia of Traditional Korean Medicine), in collaboration with universities. Furthermore, we are making progress in the development of ingredients for health functional foods.
For finished pharmaceutical product business, we are mainly focused on tablets, soft capsule and hard capsule formulations supplying products like anti-inflammatory analgesics, neurotic disorder treatments, and vitamin supplements both domestically and internationally.
In addition, by establishing the Open Innovation Center (OIC), we are striving to pioneer new business areas through cooperation beyond competition with companies, universities, and research institutes that are experiencing difficulties in commercialization. In addition, by participating in the OIC, partners can receive shared access to our AI-enabled molecule structure design and molecule synthesis technology through our extensive team of synthesis researchers. They can also benefit from support for scaling up and commercial production according to the development stage. Furthermore, through collaboration with open innovation partners, they have the opportunity to participate in various cooperative efforts, including bioassays.
